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Summary 
Liquid-liquid phase separation has been recognized to underlie the formation 
and disassembly of liquid, membrane-less organelles in cells, but cellular 
mechanisms that control this phenomenon remain poorly understood. A 
prominent example of regulated and reversible segregation of liquid phases may 
occur during mitosis, when membrane-less organelles disappear upon nuclear 
envelope breakdown and reappear as mitosis is completed. Here we show that 
the dual-specificity kinase DYRK3 acts as a central dissolvase of several types of 
membrane-less organelles during mitosis. DYRK3 kinase activity is essential to 
prevent the unmixing of the mitotic cytoplasm into aberrant liquid hybrid 
organelles and the over-nucleation of spindle bodies. Our work supports a 
mechanism in which the dilution of phase-separating proteins during nuclear 
envelope breakdown and the DYRK3-dependent degree of their solubility allow 
cells to dissolve and condense several membrane-less organelles during mitosis. 
 
A fundamental property of inhomogeneous crowded fluids is their ability to display 
coacervation, electrostatically-driven liquid-liquid phase separation of molecules that 
can lead to the emergence of micro-compartments1,2. This phase separation paradigm 
has in recent years been successfully applied to explain the formation of numerous 
membrane-less organelles in cells, driven by intrinsically disordered regions in 
proteins and weak multivalent interactions3–5, and often aided by polymeric scaffolds 
such as RNA to which these proteins bind6,7, and which themselves can induce phase 
separation8. However, as with all cellular processes, various gene functions and 
enzyme activities must have evolved to modulate the underlying physicochemical 
phenomenon, to drive it out of equilibrium, or push it across critical boundaries to 
make it advantageous for living systems. 
 
We previously discovered that upon cellular stress, the dual-specificity kinase 
DYRK3 partitions into stress granules via its intrinsically disordered N-terminal 
domain and that its kinase activity is required for the dissolution of stress granules, 
likely by phosphorylating multiple RNA-binding proteins9. Subsequently, it was 
shown that MBK-2, the C. elegans homologue of DYRK3, controls the dissolution of 
P-granules during the first cell division of the embryo10. In addition, POM1, a S. 
pombe relative of DYRK3, displays reversible clustering11 and controls the presence 
of protein assemblies involved in cytokinesis12, which may also involve phase 
separation. Thus, DYRK-family kinases could represent a novel class of 
evolutionarily conserved cellular regulators that control phase transition phenomena 
in cells, serving various cell-physiological purposes.  
 
A particularly dramatic example of such control may occur during mitosis. It is long 
known that numerous membrane-less organelles in both the cytoplasm and the 
nucleus disappear during mitosis, or, in the case of stress granules, cannot be induced 
to form in mitotic cells13–15. However, the physical principles and the molecular 
mechanisms behind these phenomena have remained unclear. We here investigate 
whether DYRK3 acts as the dissolvase in these processes, and how this is coordinated 
with the cell cycle. 
 
DYRK3 interactome and localization 
To identify proteins interacting with DYRK3 in unperturbed cells, we performed 
quantitative affinity purification using stable isotope labelling with amino acids in cell 
culture (SILAC)-based quantitative proteomics16. From two independent label swap 
experiments (forward and reverse) (Extended Data Fig. 1a), we identified a total of 
251 proteins interacting specifically with transiently overexpressed GFP-tagged 
DYRK3 (Fig. 1a, Table S1). The majority (86%) of these proteins are known to bind 
RNA, and amongst them are also multiple components of stress granules, splicing 
speckles, and the centrosome or pericentriolar matrix (Fig. 1a).  Moreover, when we 
treated cells with GSK-626616, a small compound inhibitor of DYRK39, many of 
these interactions became more prominent (Fig. 1b, Extended Data Fig. 1b,c and 
Table S2), which were not caused by an increase in the abundance of interactors or 
DYRK3 itself (Extended Data Fig. 1d,e). 
 
Overexpression of DYRK3 leads to its spontaneous phase separation at a specific 
concentration threshold9. To investigate its subcellular localization at near-
endogenous levels, we created an inducible cell line. At very low induction levels 
(∼30% of endogenous levels) (Extended Data Fig. 2a), GFP-DYRK3 shows a diffuse 
distribution within the nucleus and the cytoplasm, but also an enrichment in 
centrosomes (Pericentrin) and pericentriolar matrix (PCM1) (Fig. 1c), and in splicing 
speckles (SC35) (Fig. 1d). Inhibition of DYRK3 leads to a further accumulation in 
splicing speckles, and to a visible increase in splicing speckle size (Fig. 1d). 
Consistent with our previous findings9, GSK-626616-inhibited GFP-DYRK3 also 
accumulates in arsenite-induced stress granules (PABP1) at these low expression 
levels (Extended Data Fig. 2b). In mitotic cells, we observed that GFP-DYRK3 
localizes to spindle poles, and that it accumulates in small granules that grow in size 
when its kinase activity was inhibited (Fig. 1e and Extended Data Fig. 2c). 
 
Mitotic effects of DYRK3 inhibition 
Since DYRK3 associates with membrane-less organelles in both the nucleus and the 
cytoplasm, accumulates in granules in mitotic cells when inhibited, and interacts with 
proteins that are heavily phosphorylated during mitosis, of which some sites are 
sensitive to DYRK3 inhibition9 (Extended Data Fig. 2d), we decided to investigate its 
role during mitosis, when the contents of both cellular compartments mix. Strikingly, 
we found that inhibition of DYRK3 in mitotic cells leads to aberrant condensations of 
splicing speckle marker SC35 (Fig. 2a and Extended Data Fig. 3a), stress granule 
marker PABP (Fig. 2b and Extended Data Fig. 3b) and pericentriolar matrix protein 
PCM1 (Fig. 2c and Extended Data Fig. 3c). Aberrant condensations were observed in 
two different human cell lines and for multiple markers (Extended Data Fig. 3d-f). 
Importantly, testing a panel of inhibitors of kinases known to regulate centrosome 
biogenesis or splicing speckle composition in interphase cells did not show these 
effects (Extended Data Fig. 3g). Moreover, GSK-626616 does not cause the 
accumulation of SRPK117 or CDK1, a key regulator of entry into mitosis, in these 
aberrant condensations, nor does it affect their activation or activity inside cells 
(Extended Data Fig. 4a-f) or in vitro9, while RNAi-mediated knockdown of DYRK3 
recapitulated the GSK-626616 effects (Extended Data Fig. 4g).  
 
Interestingly, splicing speckle, stress granule, and pericentriolar matrix markers co-
condensed into the same hybrid structures, which also stained positive for poly-
adenylated RNA and accumulated inhibited DYRK3 (Fig. 2d,e and Extended Data 
Fig. 5a,b). Not all markers of membrane-less organelles condensed into these 
structures, since P-bodies, nucleoli, and Cajal bodies appeared to dissolve normally 
during mitosis when DYRK3 is inhibited (Extended Data Fig. 5c-e). The aberrant 
condensates are not classical aggresome-like structures, since they do not stain 
positive for ubiquitin (Extended Data Fig. 5f). Timelapse analysis of mitotic granule 
formation using mCherry-tagged SRRM2, a splicing speckle protein, revealed that 
they appear fast (within 15-20 min) upon DYRK3 inhibition (Fig. 2f and 
Supplementary Video 1) and display liquid-like merging (Extended Data Fig. 6a), 
while photobleaching the granules showed that SRRM2 exchanges rapidly (t1/2 ∼10 
sec) and completely between the condensed and dissolved phases (Fig. 2g). The total 
amount of SRRM2 in cells did not change during granule formation (Extended Data 
Fig. 6b), and the accumulation of SRRM2 in the condensed phase was a consequence 
of its depletion from the dissolved phase (Extended Data Fig. 6c). Thus, DYRK3 
kinase activity is essential during mitosis to prevent the formation of aberrant liquid-
liquid phase-separated hybrid condensates consisting of nuclear and cytoplasmic 
proteins and RNA, by keeping the condensation threshold of its substrates high. 
 
DYRK3 dissolvase activity 
To prevent aberrant condensation, DYRK3 may act as a dissolvase of multiple liquid-
unmixed compartments. When we overexpressed wildtype GFP-DYRK3 in interphase 
cells, we observed dissolution of splicing speckles in the nucleus (Fig. 3a,b and 
Extended Data Fig. 7a). This dissolving effect was dependent on its kinase activity, as 
it was reversed by treating cells with the DYRK3 inhibitor, and was not observed 
when overexpressing a kinase-dead point mutant of GFP-DYRK3 (Fig. 3a,b and 
Extended Data Fig. 7a,b). Moreover, a nuclear localization sequence mutant of 
DYRK3 prevented the dissolution of splicing speckles, while exclusive nuclear 
localization of DYRK3 completely dissolved splicing speckles, indicating the 
requirement for direct interaction with its substrates (Extended Data Fig 7c,d). 
 
Similarly, we found that overexpression of GFP-DYRK3 dissolves pericentriolar 
satellites and prevents the induction of stress granules with arsenite in the cytoplasm 
in a kinase activity-dependent manner (Fig 3c-f and Extended Data 7e-h). 
Furthermore, phase-separated structures formed by overexpressing an intrinsically 
disordered domain of PCM1 (1-1468)14 and SRRM1, a highly intrinsically disordered 
interactor of DYRK3 and known splicing speckle component (Extended Data Fig. 7i), 
are completely dissolved by DYRK3 in a kinase-dependent manner (Extended Data 
Fig. 7j-l). We did not observe a dissolving effect of overexpressed DYRK3 on 
nucleoli (Extended Data Fig. 7m), consistent with the observation that these 
organelles still dissolve in DYRK3-inhibited mitotic cells. This shows that kinase-
active DYRK3 has dissolvase activities for multiple but not all membrane-less 
organelles, both in the cytoplasm and in the nucleus.  
 
DYRK3 to substrate ratio drives phase transition 
Upon entry into mitosis, membrane-less organelles disappear, and then re-appear 
during telophase or after completion of mitosis13–15,18. If disappearance occurs through 
a dissolution process driven by DYRK3, then its dissolvase activity must rapidly 
increase at the beginning of mitosis and then reduce at the end of mitosis. When we 
analysed the protein levels of endogenous DYRK3 along the cell cycle, we observed 
that its expression increases as cells progress from late S to the end of G2 (Fig. 4a). 
Yet, cells in late G2 display splicing speckles in the nucleus and can condense stress 
granules in the cytoplasm upon stress13,15,18. Furthermore, we did not observe a 
sudden increase in DYRK3 levels as cells enter mitosis (black box in Fig. 4a). 
 
One explanation could be that the concentration of DYRK3 relative to its substrate 
suddenly increases upon nuclear envelope breakdown. This occurs because key 
substrates of DYRK3 are exclusively located in either the nucleus (SRRM1) or the 
cytoplasm (PCM1), resulting in their dilution when the compartment barrier is 
removed (Fig. 4b and Extended Data Fig. 8a-d). And because DYRK3 itself is located 
in both compartments and does not get similarly diluted, the DYRK3 to substrate ratio 
increases by a factor of 2-3 (Fig. 4b) as cells transition from G2 into M. To 
investigate whether such an increase in ratio is necessary and sufficient to ensure 
complete dissolution of membrane-less organelles during mitosis, we transiently 
transfected inducible wildtype GFP-DYRK3 along with mCherry-SRRM1 in non-
mitotic cells. From a large number of single cells covering a wide range of expression 
levels and DYRK3 to SRRM1 ratios, we determined an intracellular phase diagram of 
SRRM1 in a condensed or dissolved phase as a function of DYRK3 and SRRM1 
levels. This revealed a remarkably sharp phase boundary at a specific DYRK3 to 
SRRM1 ratio across a large range of expression levels, below which SRRM1 would 
be condensed and above which it would be dissolved (Fig. 4c). Furthermore, by 
following interphase cells through time-lapse imaging, we could observe how changes 
in concentration of the components determines granule phase behaviour as mapped in 
the phase diagram. Cells in which the DYRK3 to SRRM1 ratio increased over time 
displayed a sudden transitioning from a condensed SRRM1 phase to a dissolved 
phase when the phase boundary was crossed (Cell 1 and 2 in Fig 4d). While SRRM1 
remained dissolved in cells that always displayed a high DYRK3 to SRRM1 ratio and 
stayed above the phase boundary over time (Cell 3 in Fig. 4d).  
 
We next focussed on single cells with low, near-endogenous levels of GFP-DYRK3 
and mCherry-SRRM1 that entered mitosis during the time-lapse recording. When we 
plotted single-cell time-traces of DYRK3 to SRRM1 ratios into the phase diagram, 
and marked when SRRM1 becomes dissolved, we observed that this occurs right at 
the moment of crossing the phase transition boundary (Cell 1 and 2 in Fig. 4e), due to 
the sudden, 2.7-fold increase in DYRK3 to SRRM1 ratio during the G2-to-M 
transition (marked by arrowheads in Fig. 4e). Consistently, when we followed a cell 
with high levels of overexpressed SRRM1 and a consequently very low DYRK3 to 
SRRM1 ratio far away from the phase transition boundary, the 2.7-fold increase in 
ratio during the G2-to-M transition was not sufficient to cross the boundary, resulting 
in the persistence of SRRM1 granules in mitotic cells (Cell 3 in Fig. 4e). We observed 
this effect invariably in single cells that overexpress SRRM1 beyond a critical 
concentration, at which point levels of endogenous DYRK3 were insufficient to 
trigger a phase transition upon mitotic entry (Fig. 5a). These cells show mitotic 
SRRM1 granules (Fig. 5a) that recruit endogenous splicing speckle proteins 
(Extended Data Fig. 8e), which also undergo liquid-like merging, and show rapid 
exchange of SRMM1 between the condensed and dissolved phase, which is under the 
control of DYRK3 (Extended Data Fig. 8f, g). Furthermore, we observed that the 
dilution effect alone is not sufficient. When we arrested cells in mitosis after nuclear 
envelope breakdown with a single thymidine-nocodazole block, and splicing speckles 
are dissolved, acute treatment with the DYRK3 inhibitor results in the appearance of 
aberrantly condensed structures (Extended Data Fig. 8h), indicating that DYRK3 
kinase activity is required to maintain the dissolved phase during mitosis. 
 
Aberrant granules delay mitotic progression 
We next asked whether the aberrant co-condensation of proteins in mitotic cells has a 
consequence for mitotic progression. We found that when cells are treated with the 
DYRK3 inhibitor, they display a prolonged mitotic length, and often a mitotic arrest 
(Fig. 5a). Interestingly, we also found a prolonged mitotic length in cells that were 
unable to completely dissolve mitotic granules upon nuclear envelope breakdown due 
to very high levels of overexpressed SRRM1, even when DYRK3 activity was not 
compromised (Fig. 5a). This suggests that mitotic defects are, in part, caused by an 
inability to keep proteins dissolved in mitotic cells. Strikingly, while centrosome 
duplication appears to occur normally in DYRK3-inhibited cells, gamma-tubulin 
displays multiple condensation foci (Extended Data Fig. 9a), resulting in the frequent 
occurrence of multipolar spindles (Fig. 5b). To explain this, we searched the DYRK3 
interactome for possible mitotic regulators that might have an impact on mitosis. This 
revealed that BuGZ (ZNF207) and its interaction partner Bub3, are enriched in the 
DYRK3 interactome upon GSK-626616 treatment (Fig. 5c). BuGZ is required for 
spindle matrix assembly through liquid-liquid phase separation19, and localizes to 
splicing speckles in interphase cells20 (Extended Data Fig. 9b). When we analysed its 
localization in mitotic cells, we found that upon DYRK3 inhibition, also BuGZ 
becomes sequestered in mitotic granules where it co-localizes with inhibited DYRK3 
(Extended Data Fig. 9c, d) and PABP (Fig. 5c). Thus, DYRK3 releases mitotic 
regulators from liquid-unmixed compartments at the onset of mitosis and keeps them 
dissolved during mitosis. When this is compromised, such mitotic regulators are 
sequestered in mitotic granules, which interferes with their normal roles during 
mitosis leading to mitotic defects.   
 
At the end of mitosis, reassembly of the nuclear envelope and the re-accumulation of 
DYRK3 substrates in their respective compartments should lead to a drop in the 
DYRK3 dissolvase to substrate ratio below the critical point and reverse this process. 
However, some membrane-less organelles, such as splicing speckles, re-condense 
already in telophase18, before the nuclear envelope has been reassembled. Strikingly, 
we noticed that DYRK3 is abruptly degraded at the boundary between M and G1 (red 
box in Fig. 4a and Fig. 5d), suggesting that re-condensation before nuclear envelope 
reassembly may rely on rapidly removing DYRK3. Progression through mitosis and 
entry into G1 is driven by the Anaphase Promoting Complex/Cyclosome (APC/C 
complex), which promotes the ordered ubiquitination and subsequent degradation of 
multiple D-box (RXXL)-containing substrates through mitosis21. We found that 
DYRK3, which contains a D-box, interacts with both APC/C co-activators Cdc20 and 
Cdh1, resulting in its targeting to ubiquitin-positive aggregates in the cytoplasm and 
its degradation (Fig. 5e and Extended Data Fig. 10a-d), consistent with the 
identification of DYRK3 as a novel APC/C substrate22. Moreover, when we 
overexpressed GFP-DYRK3 in mitotic cells to levels that cannot be degraded by 
APC/C, splicing speckles remain dissolved in telophase, indicating that APC/C-
mediated degradation of DYRK3 at the end of mitosis is involved in their re-
condensation process (Extended Data Fig. 10e).  
 
Discussion 
We have here uncovered a mechanism by which multiple membrane-less organelles 
dissolve during mitosis and re-condense as mitosis completes. The dual-specificity 
kinase DYRK3 plays a key role in this process by acting as the dissolvase of these 
organelles. This extends our previous finding that DYRK3 dissolves stress granules 
during stress recovery9. Importantly, not all membrane-less organelles that disappear 
during mitosis, such as P-bodies and nucleoli, are dissolved by DYRK3. This may 
suggest a different physico-chemical phenomenon that underlies the formation of 
these organelles, or a role for other kinases, possibly relatives of DYRK3, that 
mediate their dissolution. 
 
The organelles that are dissolved by DYRK3 all contain protein and RNA, and form 
by liquid-liquid phase separation. DYRK3 binds to proteins that are key components 
of these organelles, and is a proline-directed kinase with broad specificity23 that 
phosphorylates multiple serine and threonine residues in unstructured domains9. This 
may affect the electrostatic properties of these domains such that it alters the 
condensation threshold of these proteins. When the active concentration of DYRK3 
becomes high enough relative to its substrates, it triggers a transition from the 
condensed to the dissolved phase, which will remain to exist as long as this ratio stays 
sufficiently high. The ratio can be modulated in multiple ways. At the onset of 
mitosis, the loss of the nucleus-cytoplasm compartment boundary is exploited to alter 
the DYRK3 to substrate ratios such that it results in a phase transition. For some 
organelles, degradation of the dissolvase is used to trigger a phase transition in the 
opposite direction. Thus, progression through the cell cycle can be conceived as a 
process where cells cycle through a phase diagram (Fig. 6). Also, when compartment 
boundaries stay intact, a specific accumulation or depletion of substrate in one 
compartment may alter the ratio sufficiently to induce a phase transition which may 
occur during cellular stress24. In addition, the ratio could be altered by increasing the 
abundance or activity of DYRK3 by specific upstream regulators, which could be 
coupled to different physiological processes such as the cell cycle23,25 .   
 
We currently do not understand how at the end of mitosis, and upon degradation of 
DYRK3, aberrant co-condensation is prevented. One possibility is that the kinetics or 
regulation of dephosphorylation of DYRK3-phosphorylated residues in proteins is 
component- or compartment-specific, as may be the levels of dephosphorylation 
required to initiate phase transition. In addition, since cytoplasm and nucleus 
compartment boundaries become re-established right at this time, which may 
contribute to preventing aberrant co-condensation.  
 
Multiple aspects of mitosis are compromised when the DYRK3 to substrate ratio 
cannot display its natural dynamics. Its increase allows the release of mitotic 
regulators from liquid-unmixed compartments as cells enter mitosis and prevents their 
aberrant co-condensation during mitosis. In addition, preventing co-condensation 
during mitosis could be important to ensure homogeneous distribution of proteins and 
RNA between daughter cells during symmetric cell division, which may then be 
additionally regulated to achieve differential condensation points in daughter cells 
during asymmetric cell division10,26. Finally, through its ability to control the 
condensation of multiple compartments, DYRK3 may link structural and functional 
roles for RNA, transcription, and splicing to the assembly of the mitotic spindle27–29, 
and be involved in the maintenance of the pericentriolar matrix. We propose that 
DYRK family kinases represent an evolutionarily conserved novel class of regulators 
that control liquid-liquid unmixing phenomena in cells crucial for a variety of cell-
physiological processes.  
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Supplementary Information 
 
Supplementary Figure 1.  
Source data for gels 
Table. S1 
List of detected DYRK3 specific interaction partners. 
Table. S2 
List of detected DYRK3 specific interaction partners upon GSK-626616 inhibitor 
treatment 
 
Supplementary Video 1 
SRRM2-mCherry granule formation upon GSK-626616 inhibitor treatment 
HeLa cell expressing SRRM2-mCherry was arrested in mitosis by thymidine-
nocodazole block. Time-lapse movie shows SRRM2 granule formation on addition of 
GSK-626616 (1 µM).  Time point (0 min) corresponds to GSK-626616 addition. 
Scale bar is 10 µm. Movie is representative of atleast three independent experiments. 
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Main Figure Legends 
 
Figure 1. DYRK3 interacts with multiple membrane-less compartments  
 
a 
Scatter plot of DYRK3-specific interactors determined by double-SILAC pull-down 
and MS. 
b 
Examples of DYRK3 interactions that increase upon GSK-626616 treatment. Error 
bar represents the standard error of the median. (n) indicates the number of peptide 
evidence ratios included for calculating the protein ratio in one triple-SILAC pull-
down. 
c 
Colocalization of GFP-wildtype (WT) DYRK3 with centrosomes. 
d 
Colocalization of GFP-wildtype (WT) DYRK3 with splicing speckles and increase 
upon GSK-626616 treatment (1µM, 2hrs). 
e 
Mitotic cells show formation of DYRK3-positive granules (arrowheads) upon GSK-
626616 treatment (1µM, 4hrs). 
 
Images are representative of at least three independent experiments. Scale bars: 10 
µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Formation of mitotic hybrid compartments upon DYRK3 inhibition 
 
a 
Top: Mitotic SC35 granules upon GSK-626616 treatment (1µM, 1hr).  
Bottom: Quantification of metaphase SC35 granule number (3 independent 
experiments). 
b 
Top: Mitotic PABP granules upon GSK-626616 treatment (1µM, 3hr).  
Bottom: Quantification of metaphase PABP granule number (3 independent 
experiments). 
c 
Top: Mitotic PCM1 granules upon GSK-626616 treatment (1µM, 6hr).  
Bottom: Quantification of metaphase PCM1 granule number (3 independent 
experiments). 
d 
Colocalization of splicing and stress granule markers in hybrid compartments in 
mitotic cells upon GSK-626616 treatment (1µM, 6hr). 
e 
Colocalization of splicing and pericentriolar satellite markers in hybrid compartments 
in mitotic cells upon GSK-626616 treatment (1µM, 6hr). 
f 
Time-lapse images show SRRM2-mCherry granule formation upon GSK-626616 
(1µM) treatment in cells arrested in mitosis. 
g 
FRAP trajectories of mitotic SRRM2-mCherry granules in presence of GSK-626616 
(1µM). Images show FRAP recovery. Data are Mean ± SD.  
 
Box plots: central mark: population median; box: interquartile range; whiskers: 1st/3rd 
quartile ± 1.5* interquartile range; outliers: dots. Statistical analysis performed across 
cells by Welch two-sided t-test. 
  
Data and images are representative of at least three independent experiments. Scale 
bars: 10 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. DYRK3 over-expression dissolves membrane-less compartments 
 
a  
Splicing speckle dissolution upon overexpressing wildtype (WT) DYRK3, and not 
kinase-dead (K218M) DYRK3.  
b 
Quantification of splicing speckle dissolution.  
c 
Pericentriolar satellite dissolution upon overexpressing wildtype (WT) DYRK3, and 
not kinase-dead (K218M) DYRK3. 
d 
Quantification of pericentriolar satellite dissolution. 
e 
Stress granule dissolution upon overexpressing wildtype (WT) DYRK3, and not 
kinase-dead (K218M) DYRK3. Arsenite treatment (500µM, 45mins).  
f 
Quantification of stress granule dissolution. 
 
* denotes transfected cells. Data and images are representative of at least three 
independent experiments. Data are Mean ± SD. Scale bars: 10 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Increase in DYRK3 to substrate ratio during mitosis drives dissolution 
of phase-separated compartments 
 
a 
Western blot analysis of endogenous DYRK3 levels in cells synchronized in mitosis 
(thymidine-nocodazole) and released for indicated times.  
b 
Left: Nuclear intensity change during G2 to M transition. GFP-wildtype DYRK3 
(green), mCherry-SRRM1 (red) and GFP-wildtype DYRK3: mCherry-SRRM1 ratio 
(blue). Data are Mean ± SD (n= 9 cells, 3 independent experiments). 0 min refers to 
nuclear envelope breakdown. 
Right: Time-lapse images of a cell (single Z-stack) transitioning from G2 to M.   
c 
GFP-wildtype DYRK3 and mCherry-SRRM1 nuclear intensities for a population of 
cells. 
Data points (single cells): colour-coded for SRRM1 state.  
d 
Left: Trajectory of three interphase cells expressing inducible GFP-wildtype DYRK3 
and mCherry-SRRM1, mapped onto the phase diagram of Fig. 4C. The trajectories 
are colour coded for fraction of SRRM1 granules compared to first time point 
(TP:01). 
Right: Time-lapse images of the cells shown in the left panel.  
e 
Left: Trajectory of three cells expressing inducible GFP-wildtype DYRK3 and 
mCherry-SRRM1 transitioning through cell-cycle stages, mapped on the phase 
diagram (Fig. 4C). The trajectories are colour coded for cell cycle stages and fraction 
of SRRM1 granules compared to first time point (TP:01). Inset: DYRK3: SRRM1 
ratio plotted for the three trajectories. Arrowheads show G2 to M transition. 
Right: Time-lapse images of the cells shown in the left panel.  
 
Data in Fig. 4 a, c-e are representative of two independent experiments. Scale bars: 10 
µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mitotic defects on DYRK3 inhibition and APC/C dependent 
degradation of DYRK3 
 
a 
Top left: Mitotic length plotted as a function of mCherry-SRRM1 nuclear intensity (in 
G2 phase). Data points (single cells): colour-coded for metaphase SRRM1 state. 
Top right: Increase in mitotic length upon GSK-626616 treatment (1µM) (3 
independent experiments). 
Bottom: Time-lapse images of cells marked in the top panel.  
b 
Formation of aberrant granules and multipolar spindles in mitotic cells upon GSK-
626616 treatment (1µM, 6hrs). 
c 
Left: Increase in the interaction of DYRK3 with BUB3 and ZNF207 upon GSK-
626616 treatment. Error bar represents the standard error of the median. (n) indicates 
the number of peptide evidence ratios included for calculating the protein ratio in one 
triple-SILAC pull-down experiment.  
Right: Co-localization of spindle matrix and stress granule markers in mitotic cells 
upon GSK-626616 treatment (1µM, 3hr).  
d 
Western blot quantifications of the relative density of DYRK3 during M and early G1 
(M+2 hrs). Data are Mean ± SD. 
e 
Top: DYRK3 interacts with APC/C co-activators Cdc20 and Cdh1. HA-Cdh1 and 
HA-Cdc20 probed with anti-HA antibody. GFP and GFP-DYRK3 probed with anti-
GFP antibody. 
Bottom: Endogenous DYRK3 is degraded by overexpressed HA-Cdh1 and HA-
Cdc20 (3µg, 48hr) in HEK293T cells. 
Box plots: central mark: population median; box: interquartile range; whiskers: 1st/3rd 
quartile ± 1.5* interquartile range; outliers: dots. Statistical analysis performed across 
cells by Welch two-sided t-test.  
Images and data are representative of at least three independent experiments. Scale 
bars: 10 µm  
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  
 
Model showing membrane-less organelles transitioning through a phase diagram 
during the cell cycle. DYRK3 perturbation shifts the phase boundary resulting in the 
formation of hybrid compartments in mitotic cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
Cell culture 
HeLa cells were a kind gift from Marino Zerial (MPI-CBG, Dresden), Hela-FlpIn-
Trex cells were a kind gift from Ivan Dikic (Goethe University, Frankfurt)30 and 
HEK293T cells were from ATCC (Molsheim Cedex). Hela and HEK293T cells were 
maintained in 10-cm dishes in DMEM supplemented with 10% fetal bovine serum 
(Sigma-Aldrich) and L-Glutamine (Sigma-Aldrich). Hela-FlpIn-Trex cells were 
maintained in 10-cm dishes in DMEM supplemented with 10% tetracycline-free fetal 
bovine serum (Clonetech Laboratories), L-Glutamine and blasticidin (1µg/mL, Santa 
Cruz). Hela-FlpIn-Trex expressing GFP-wildtype DYRK3 was induced using 
doxycycline (Sigma) with indicated time and concentration.  All cells were 
maintained in a humidified incubator at 370C under 5% CO2. All cell lines were 
regularly tested for Mycoplasma contaminations. Test results were negative. For 
imaging experiments, cells were grown in 96-well plates (Greiner Bio-One 
International). 
 
Inhibitors 
GSK-626616 (PubChem CID: 15981157) was obtained from Tocris Bioscience. 
DMSO was from Sigma-Aldrich (D2438). The following inhibitors were used in this 
study: GW 843682X (Tocris Bioscience, 2977), ZM 447439 (Tocris Bioscience, 
2458), Barasertib (Selleck chemicals, S1147), Volasertib (Selleck chemicals, S2235), 
VX-680 (Selleck chemicals, S1048), TCA 2317 HCl (Tocris Bioscience, 4066), 
KHCB19 (Tocris Bioscience, 4262), KHCB19 (Calbiochem, Merck Millipore, 
219511), TG003 (Tocris Bioscience, 4336), SRPIN340 (Santa Cruz, sc-394310) and 
SRPIN340 (Tocris Bioscience, 5063). Prior to inhibitor treatments, cells were washed 
and serum deprived for 2 hrs. 
 
Generation of Hela-FlpIn-Trex expressing GFP-wildtype DYRK3 
Hela-FlpIn-Trex cells were co-transfected with plasmids, pcDNA5/FRT/TO-GFP-
wildtype DYRK3 and Flp recombinase expression vector (pOG44) for 48 hrs, and 
then selected with hygromycin (250µg/mL, Thermo Fisher Scientific) for two weeks. 
Monoclonal cells were isolated by limiting-dilution technique, and then expanded. 
 
SILAC cell culture 
HEK293T cells (ATCC, Manassas, USA) were cultivated using SILAC DMEM 
media (Life Technologies) containing (“light”) Lys-0: L-lysine-12C614N2, Arg-0: L-
arginine-12C614N4, or (“medium”) Lys-4: L-lysine-12C614N22D4, Arg-6: L-arginine-
13C614N4, or (“heavy”) Lys-8: L-lysine-13C615N2, Arg-10: L-arginine-13C615N4 and 
supplemented with 10% dialyzed fetal bovine serum (PAA Laboratories, Cölbe, 
Germany), 4 mM Glutamax and 1 mM sodium pyruvate. Cells were maintained in a 
humidified incubator under 5% CO2 at 37°C.  
 
SILAC quantitative pull-down assays 
To study interaction partners of DYRK3, a label-swap SILAC pull-down experiment 
was set up as depicted in Extended data Fig. 1a. Plasmids containing EGFP only or 
EGFP- wildtype DYRK3 were transiently transfected into SILAC-labelled HEK293T 
cells using linear polyethylenimine (PEI) transfection reagent (Polysciences, 
Warrington, PA). Cells of different SILAC states were harvested 48 h post-
transfection and lysed separately using a Dounce homogenizer in lysis buffer 
containing 25 mM Tris/HCl pH 7.4, 125 mM KCl, 1 mM MgCl2, 1 mM EGTA/KOH 
pH 8.0, 5% glycerol, 1% Triton X-100 and freshly added protease inhibitor cocktail 
(Roche). The cleared lysates were then incubated with anti-GFP agarose beads 
(Chromotek) at 4 °C for 90 min. After that, the beads were washed two times in 
buffer I (25 mM Tris/HCl pH 7.4, 125 mM KCl, 1 mM MgCl2, 1 mM EGTA/KOH 
pH 8.0, 5% glycerol, 0.1% Triton X-100) followed by one wash in buffer II (1 mM 
Tris/HCl pH 7.4, 150 mM KCl, 1 mM MgCl2). Beads of different SILAC states were 
combined during the final washing step. Proteins were then eluted by heating the 
beads to 90 °C in 8 M guanidinium chloride and precipitated in ethanol at 4 °C. 
A separate triple-SILAC pull-down experiment was carried out to study the impact of 
DYRK3 inhibitor (GSK-626616) on DYRK3 interactions as shown Extended data 
Fig. 1b. Briefly, 24 h post-transfection, cells were further treated with or without 10 
µM GSK-626616 inhibitor for 2 h. The remaining steps of the pull-down experiment 
were then conducted as described above. 
Precipitated proteins were resolubilized in 6M urea/2M thiourea buffer (10 mM 
HEPES pH 8.0). Proteins were then reduced by dithiothreitol and akylated by 
iodoacetamide in the dark, followed by sequential digestion in solution using lysyl 
endopeptidase (Lys-C, Wako) for 3 h and trypsin (Promega) overnight at room 
temperature as reported previously31. Peptides were desalted and purified by solid 
phase extraction in C18 StageTips32. 
 
Liquid chromatography tandem mass spectrometry 
Peptide separation was done online by reversed phase chromatography using an in-
house packed column (inner diameter: 75 µm; ReproSil-Pur C18-AQ 3-µm resin, Dr. 
Maisch GmbH) through a 120-min gradient of acetonitrile (8-50%) with 0.1% formic 
acid at a nanoflow rate of 200 nl/min. Eluted peptides were sprayed directly by 
electrospray ionization into a Q Exactive Plus Orbitrap mass spectrometer (Thermo 
Scientific). Mass spectra were acquired in data-dependent mode using a top10 
sensitive method. Each duty cycle consisted of one full scan (resolution: 70,000, 
target value: 3 × 106, scan range: 300 to 1,700 m/z) and 10 MS/MS scans of fragment 
ions produced via higher energy collision dissociation (HCD; resolution: 35,000, 
target value: 5 × 105, maximum injection time: 120 ms, isolation window: 4.0 m/z). 
Precursor ions with unassigned or +1 charge state were not selected for fragmentation 
scans.  Dynamic exclusion time was 30 s. 
 
Mass spectrometry data processing 
All mass spectrometry raw data were processed using MaxQuant software package 
(version 1.5.5.1)33 with built-in Andromeda search engine34. Spectral data were 
searched against a target-decoy database containing the forward and reverse protein 
sequences of UniProt human proteome release 2016_06 (92,578 entries), EGFP and 
the default list of 245 common contaminants. Corresponding SILAC labels were 
selected for the double- or triple-SILAC experiment. A maximum of 3 SILAC 
labelled amino acids were allowed for each peptide. Trypsin/P specificity was 
assigned. Carbamidomethylation of cysteine was chosen as fixed modification. 
Methionine oxidation and protein N-terminal acetylation were set as variable 
modifications. A maximum of 2 missed cleavages were tolerated. Minimum peptide 
length of 7 amino acids was required. Each protein group must contain at least one 
unique peptide. False discovery rate (FDR) was set to 1% for both peptide and protein 
identifications. 
For SILAC protein quantification, minimum ratio count was set to one. Both the 
unique and razor peptides were used for quantification. The “re-quantify” function 
was switched on. The “advanced ratio estimation” option was also chosen. 
 
Bioinformatic data analysis 
All data analyses were performed in R statistical environment (version 3.3.1). To 
normalize the pull-down data, protein ratios were first log-transformed. Under the 
assumption that the majority of detected proteins were non-specific background 
binders, the distribution of protein ratios was assessed using kernel density estimation 
to find the peak density. Protein ratios were then normalized by adjusting to the point 
at which peak density was found. Further for the triple-SILAC pull-down data, 
proteins were filtered to retain only those with a normalized H/L or M/L log2 ratio 
greater than the cut-off value of 1. The log-transformed H/M ratios were then re-
scaled with respect to the DYRK3 H/M ratio (Extended data Fig. 1c). 
Gene ontology annotation for categorizing the detected DYRK3 interaction partners 
was downloaded on 28th June 2016 from the QuickGO database35 provided by the 
European Bioinformatics Institute. The list of stress granule components was obtained 
from a review article36. 
To assess phosphorylation level changes of detected DYRK3 specific binders during 
cell cycle, quantitative phosphoproteomic data of human cell cycle were downloaded 
from Olsen et al. (2010)37. The data were filtered sequentially to retain: 1) phospho-
sites with high confidence in localization probability (class I)38; 2) phospho-sites that 
were regulated over cell cycle (changed by at least two folds from highest to lowest 
amounts); 3) phospho-sites belonging to proteins that were identified as DYRK3 
specific interaction partners in current study. The phospho-site ratios already 
normalized by changes in protein abundance were then re-scaled by z-score 
transformation and plotted as a heat map (Extended data Fig. 2d). 
The standard error of the median in Fig. 1 and Fig. 5 was computed based on the 
bootstrap (1,000 times) sampling distribution of corresponding log-transformed ratios 
of peptide evidence. Protein ratio of ZNF207 in Fig. 5c is determined by a regression 
analysis using the "advanced ratio estimation" function in MaxQuant. 
Prediction of protein low complexity region (LCR) was performed using the SEG 
algorithm with default parameters39. 
 
Cell synchronization  
Cells were synchronized in mitosis (M) by treatment with 2mM thymidine (Sigma-
Aldrich) for 22 hrs, then washed thrice with PBS and released from thymidine block 
for 5 hrs in fresh medium, followed by nocodazole (25ng/mL) (Sigma-Aldrich) 
treatment for 14 hrs. For time-course experiments, mitotic cells were harvested by 
shake-off, followed by a 3 min centrifugation at 300xg. Cells were then washed thrice 
with normal medium and released in normal medium for indicated times.  
 
Plasmids 
Generation of full-length DYRK3 plasmids, pcDNA5-GFP-wildtype DYRK3 and 
pcDNA5-GFP-K218M DYRK3 has been reported earlier9 . pcDNA5-SV40NLS-
wildtype DYRK3 and pcDNA5-SV40NLS-K218M DYRK3 constructs were 
generated by annealing  oligonucleotides 5’-
CCGGTTACCGAAGAAGAAGCGAAAGGTACA-3’ and 5’-
TTACCGAAGAAGAAGCGAAAGGTACACCGG-3’, followed by ligation into 
pcDNA5-GFP-wildtype DYRK3 and pcDNA5-GFP-K218M DYRK3 plasmids using 
AgeI restriction site. pcDNA5-GFP-wildtype DYRK3-NLS mutant plasmid was 
generated by site-directed mutagenesis using primer pair 5’-
GCTTGTGGGGGGTCGCTCAGCTGCGGGTGCAGCGGCGGGTCCCCCAGGCA
GC-3’ and 5’-
GCTGCCTGGGGGACCCGCCGCTGCACCCGCAGCTGAGCGACCCCCCACAA
GC-3’. mCherry-SRRM1 was generated by amplifying SRRM1 from Flag-SRRM140 
(Addgene plasmid, #11305) using primer pair  5’-
GCTAAGCTTCGATGGACGCGGGATTTTTCCGCGGAAC-3’ and 5’-
CATGGTACCTTATTAAGACTGTGGGGACACTTGGGCCTTC-3’, followed by 
insertion into mCherry2-C1 plasmid (kind gift from Michael Davidson, Addgene 
plasmid # 54563) using HindIII and KpnI restriction sites. pcDNA5/FRT/TO-GFP-
wildtype DYRK3 vector was generated by amplifying GFP-DYRK3 from pcDNA5-
GFP-wildtype DYRK3 using primer pair 5’-
GGTGGTACCCGCCACCATGGTGAGCAAGGGCG-3’ and 5’-
GCTGGATCCTTATTA GCTAATCAGTTTTGGCAATACACT-3’, followed by 
insertion in pcDNA5/FRT/TO plasmid9 using KpnI and BamHI restriction sites. RFP-
wildtype DYRK3 and RFP-K218M DYRK3 were generated by amplifying them from 
pcDNA5-GFP-wildtype DYRK3 and pcDNA5-GFP-K218M DYRK3 respectively, 
using primer pair 5’-
ATCGAATTCTATGAAGTGGAAAGAGAAGTTGGGGGATG-3’ and 5’-
GGTACCTTATTAGCTAATCAGTTTTGGCAATACAC-3’, followed by insertion 
into mRFP-C1 plasmid (kind gift from Robert Campbell, Michael Davidson & Roger 
Tsien, Addgene plasmid # 54764) using EcoRI and KpnI restriction sites. Full–length 
SRRM2 (NM_016333.3) was synthesized by Genscript (NJ, USA) and inserted into 
mCherry2-N1 plasmid (kind gift from Michael Davidson, Addgene plasmid # 54517) 
using KpnI and AgeI restriction sites. GFP-PCM1 (1-1468) was a kind gift from 
Andreas Merdes. EGFP-3XNLS41 was a gift from Dyche Mullins (Addgene plasmid, 
# 58468).  pmScarlet_NES_C142 was a gift from Dorus Gadella (Addgene plasmid, # 
85060). 1436 pcDNA3-Flag-HA was a gift from William Sellers (Addgene plasmid # 
10792). HA-Cdh143 and HA-Cdc2043 were a gift from Marc Kirschner (Addgene 
plasmid # 11596). 
 
Plasmid Transfections 
Transfections were performed with indicated plasmids with genejuice reagent (EMD 
Millipore) or Lipofectamine 2000 (Thermo-Fischer Scientific) as per manufacturer 
instructions. 
 
RNA FISH 
Fluorescent in situ hybridization (FISH) was performed with ATTO 488-labelled 18-
nucleotide long oligo-dT probe (Microsynth) for detecting polyA-mRNA. Probe 
hybridization was performed using reagents and protocol provided by the 
manufacturer (LGC Biosearch Technologies). Cells were grown in 96 well plates, 
fixed by adding 4% PFA for 10 mins, followed by permeabilization with 70% ethanol 
for 6 hrs at 40C. Cells were then washed with wash buffer, and incubated with the 
probe in hybridization buffer for 6 hrs at 37°C. The cells were washed again with 
wash buffer and then processed for immunofluorescence as described below. 
 
RNAi 
Cells were reverse-transfected using Lipofectamine RNAimax (Thermo-Fischer 
Scientific) according to manufacturer instructions, and grown in 96 well plates. Three 
silencer-select siRNA for DYRK3 (5’-CGGAUUUUGGAGCAUCUUA-3’, 5’-
CCAUCUAGCUUAUCGAUAU-3’and 5’-GAAAAGACAUGGAGUUAUU-3’) 
were pooled together (Thermo-Fischer Scientific). Positive (KIF11) and negative 
control silencer-select siRNA were from Thermo-Fischer Scientific. 1pmol siRNA 
was added per well of a 96 well plate. Cells were fixed 72hrs post transfection. 
 
Imaging  
Imaging was carried out on an automated spinning disk microscope from Yokogawa 
(Cell Voyager 7000), with an enhanced CSU-X1 spinning disk (Microlens-enhanced 
dual Nipkow disk confocal scanner, wide view type), a 40× 0.95 NA Olympus 
objective, a 60x 1.2 NA Olympus water-immersion objective and Andor sCMOS 
cameras (Andor, 2,560 × 2,160 pixels).  Live cell imaging experiments were 
performed with Yokogawa (Cell Voyager 7000) with 60x1.2 NA Olympus water-
immersion objective. All cells were maintained in a humidified environment at 370C 
under 5% CO2 for live imaging experiments. For nucleo-cytoplasmic dilution 
experiments (Fig. 4b and Extended data Fig. 8a-d), Hela-FlpIn-Trex cells were 
transfected with indicated plasmids for 6 hrs and then synchronized in G1-S by 
thymidine (2mM, 22hrs) followed by release in normal medium for 6 hrs before 
imaging. GFP-DYRK3 expression was induced with doxycycline (1µg/mL) for 2 hrs 
before imaging. Hoechst 33342 (0.5µg/mL, Thermo-Fischer Scientific) was added to 
stain DNA, an hour before imaging. For nucleo-cytoplasmic dilution experiments, six 
Z-stacks (1µm apart) were acquired at each time point and data stored as individual 
stacks. For other experiments, images were stored as maximum intensity projection. 
For mitotic arrest experiments, plasmids were transfected overnight, followed by 
thymidine treatment (2mM, 22hrs) and then released in normal medium for 6 hrs. 
Cells were then treated with nocodozole (25ng/mL) for 6hrs in serum-deprived 
medium to arrest cells in pro-metaphase. For experiments measuring the mean 
intensity of SRRM2-mCherry during mitotic granule formation (Extended data Fig. 6 
b and c), cells were imaged with 60x1.2 NA objective, and acquired Z stacks (0.45 
µm apart, 43 stacks) were stored as individual files. For SRRM2-mCherry and 
mCherry-SRRM1 granule fusion experiments in mitotic cells, acquired Z-stacks (1 
µm apart, 11 stacks) were stored as individual files. For experiments to calculate the 
mitotic length, Hoechst 33342 (0.5µg/mL, Thermo-Fischer Scientific) was added to 
stain DNA, an hour before imaging. Time-lapse imaging was performed with time 
interval of 10 mins. 
 
Image analysis 
Images were processed using ImageJ (http://rsb.info.nih.gov/ij/). For quantifying 
mitotic granules (SC35 granules, PABP granules and PCM1 granules) in metaphase, 
cells were manually segmented and mean cell intensity was determined for SC35, 
PABP and PCM1. Granules were determined using FIJI 3D Objects Counter plugin, 
with an intensity threshold of 2.5 X the mean mitotic cell intensity. We implemented 
an adjoining pixel cut-off of (8 pixels for SC35 granules, 12 pixels for PABP granules 
and 16 pixels for PCM1 granules; pixel size 161.3 nm x 161.3 nm)44. 90th percentile 
of granule numbers for DMSO control data in Fig. 2a and 2b were used as the cut-off 
for quantification of Extended data Fig. 3g (3 for SC-35 granule and 1 for PABP 
granule). Mitotic granules were observed and quantified in metaphase (identified 
based on DAPI staining). 
 
For nuclear dilution experiments of GFP-3xNLS, mCherry-SRRM1 and GFP-
DYRK3, the nuclei of cells in G2 phase were segmented based on Hoechst signal. For 
cytoplasmic dilution experiments of pmScarlet-NES and GFP-DYRK3, nuclear 
segmentation was performed based on Hoescht signal, and the cell segmentation was 
performed using the cytoplasmic fluorescent signal from these proteins. For 
cytoplasmic dilution experiments of PCM1 (1-1468), cells were co-transfected with 
plasmid expressing mcherry protein. Nuclear segmentation was performed based on 
Hoescht signal, and the cell segmentation was performed using the cytoplasmic 
fluorescent signal of mcherry. Mitotic cells were segmented using the fluorescent 
signal from these proteins. Mean nuclear or cytoplasmic intensity at each time-point is 
the mean intensity from four Z-stacks (1µm apart). The mean nuclear intensity at each 
time point was normalized to the intensity at time-point (-60min). For experiments 
measuring the mean intensity of SRRM2-mCherry during mitotic granule formation 
(Extended data Fig. 6b and c), sum projection of the Z-stacks (0.45 µm apart, 43 
stacks) was performed in Image J. Mitotic cells that were entirely captured within the 
Z-stacks during the course of the time-lapse movie were used for quantification. 
For experiments performed in Extended data Fig. 1d, cell and nuclear segmentation 
was performed using CellProfiler45 . Mitotic, border, mis-segmented cells, and cells 
with multiple nuclei were discarded using supervised machine learning tool, 
CellClassifier46. Mean intensity features were extracted from segmented cells and 
used for quantification. 
Mitotic length was calculated from Prophase/Pro-metaphase to Anaphase based on 
Hoescht signal. All data analyses were performed in Microsoft Excel and R statistical 
environment. Exposure and image processing has been performed similarly for all 
sub-figures in each panel. Images have been rescaled similarly in all sub-figures in a 
panel except Main Fig. 4e. In Fig. 4e the images of mCherry-SRRM1 in M phase are 
rescaled differently compared to S and G2 phase for better visualization of condensed 
and dissolved states of SRRM1. Background subtraction was performed on images by 
calculating the mean background intensity outside the cells. 
 
Statistical analysis was performed by Welch two-sided t-test in R statistical 
environment using default t-test function. 
 
Phase diagram experiment 
For phase diagram experiment (Fig. 4c, 4d and 4e), Hela-FlpIn-Trex cells were co-
transfected with pcDNA5/FRT/TO-GFP-wildtype DYRK3 and mCherry-SRRM1 for 
24 hrs and then induced with doxycycline (1µg/mL) for 2 hrs before imaging. 
Hoechst 33342 (0.5 µg/mL, Thermo-Fischer Scientific) was added to stain DNA, an 
hour before imaging. Time-lapse imaging was performed with time interval of 15 
mins. 
 
Phase diagram (Fig. 4c) was built by randomly selecting cells from multiple time 
points from the start, middle and end of the time-lapse movie.  Nuclear segmentation 
was manually performed based on Hoescht signal, and the mean nuclear intensity of 
GFP-DYRK3 and mCherry-SRRM1 was calculated from the maximum intensity 
projections. The nuclear intensities were used to determine the phase-diagram. Cells 
were annotated for  SRRM1 granules being in dissolved (≤ 3 granules) or condensed 
state (> 3 granules). Cells in interphase (Fig. 4d) or cells transitioning from interphase 
to mitosis (Fig. 4e) from the same time-lapse experiment were mapped on the 
determined phase diagram. 
 
FRAP Analysis 
Hela-FlpIn-Trex cells were grown on 8 well chambers (Ibidi GmbH, Germany). Cells 
were transfected with indicated plasmids for 24 hours, for experiments in interphase 
cells. Photo-bleaching experiments in interphase cells were performed in serum-
deprived medium. For mitotic experiments, cells were transfected overnight with 
indicated plasmids, followed by G1-S arrest with thymidine (2mM). mCherry-
SRRM1 transfected cells were released in serum-deprived medium and monitored in 
mitosis. SRRM2-mCherry transfected cells were arrested in mitosis by nocodazole (in 
serum-deprived medium). Photobleaching was performed on a Leica SP5 Mid UV-
VIS equipped with a 63x 1.4 NA, Oil, Plan-Apochromat objective. Cells were 
maintained at 370C under 5% CO2 during the course of experiment. A defined region 
was bleached 2 times at full laser power. Recovery could not be monitored for long 
durations because of mitotic granules moving out in Z-direction.  Recovery curves are 
therefore plotted for durations where the granules seemed not to move in Z-direction. 
FRAP analysis was performed using ImageJ. 
 
Immunofluorescence 
Cells were grown in 96 well plates and fixed by adding 4% PFA (Electron 
Microscopy Sciences) for 20 mins and then permeabilized with 0.2% Titon-X-100 for 
20 mins. The cells were blocked with 1% BSA in PBS (blocking buffer) before 
incubating with primary antibodies in blocking buffer for 2 hrs at room temperature, 
followed by incubation with Alexa-Fluor labeled secondary antibody (Life 
Technologies) in blocking buffer for 1 hour at room temperature. Nuclei were stained 
using DAPI (Life Technologies). Staining for γ-tubulin and pT446APC3 antibodies, 
was performed by pre-permeabilizing the cells with 0.1% Triton-X (in PBS) for 3 
mins before PFA fixation. Staining of ZNF207 (BugZ) was performed by washing 
cells with PEM buffer (100 mM PIPES, pH 6.8, 5 mM EGTA, 2 mM MgCl2) and 
permeabilized with 0.05% Triton-X (in PEM buffer) for 3 mins before PFA fixation47 
(in PEM buffer). Staining for PCM-1 antibody (Cell Signaling, 5259S), was 
performed by fixing cells with -200C methanol for 5 min followed by blocking with 
1% BSA. The following antibodies were used: PABP (1:100, Santa Cruz, sc-32318), 
G3BP (1:500, Abcam, ab56574), Pericentrin (1:400, Abcam, ab4448), SC35 (1:400, 
Sigma-Aldrich, S4045), PCM1 (1:100, Santa Cruz, sc-67204), PCM1 (1:200, Cell 
Signaling, 5259S), SRRM2 (1:600, Sigma-Aldrich, HPA041411), γ-tubulin (1:200, 
Sigma-Aldrich, T6557), SON (1:600, Sigma-Aldrich, HPA023535), SRPK1 (1:200, 
BD Biosciences, 611072), Cyclin B1 (1:800, Cell Signaling, 12231), CDK1 (1:200, 
Cell Signaling, 9116), Phospho-CDK1 (Tyr15) (1:50, Cell Signaling, 4539), β-tubulin 
(1:600, Abcam, ab6046), DDX6 (1:400, Bethyl Laboratories, A300-461A), Coilin 
(1:400, Abcam, ab87913), Fibrillarin (1:400, Abcam, ab5821), Ubiquitin (FK2) 
(1:200, Enzo Life Sciences, BML-PW8810), B-23 (1:600, Sigma-Aldrich, B0556), 
ZNF207 (1:500, Sigma-Aldrich, HPA017013), TIAR (1:200, BD Biosciences, 
610352, kindly provided by Magdalini Polymenidou, UZH, Zurich, Switzerland) and 
phospho-APC3 (T446) (1:200, kindly provided by Jan Michael Peters, IMP, Vienna, 
Austria). 
 
Western Blotting 
Samples were prepared for western blotting, as follows: Cells in culture dishes were 
washed thrice with PBS before adding lysis buffer (150 mM NaCl, 50 mM HEPES, 
1% Triton X-100, 0.1% SDS, 2mM DTT, 5mM EDTA, and 2x protease inhibitor 
cocktail in miliQ H2O), followed by scraping. Lysates were incubated for 30 mins on 
ice (with 15 second sonication every 15min). The cells were then centrifuged at 
21,000 RCF for 15 min at 40C and the supernatant was stored at -800C. Proteins in the 
lysates were denatured by addition of loading buffer and boiling for 10 min. Proteins 
were resolved by 10% SDS-PAGE and further analyzed by immunoblotting. After 
wet transfer of proteins onto a PVDF membrane (Immobilon-P, 0.45 µm, Millipore), 
membranes were incubated in 5% low fat milk in 1XPBST (1XPBS, 0.1% Tween-20) 
for 1 hour at room temperature. Membranes were then probed with primary antibodies 
in 3% BSA in 1xPBST for 2 hrs at room temperature, followed by incubation with 
HRP-conjugated secondary antibodies (1:5000) in 5% low fat milk in 1xPBST for 1 
hour at room temperature. For detecting DYRK3, PABP and G3BP membranes were 
incubated with primary antibody for 24 hrs at 40C. Signal was revealed with HRP 
substrate solution. The following antibodies were used: DYRK3 (1:1000, abcam, 
ab155949), GFP (1:1000, Cell Signalling, 2956), Pan-Actin (1:1000, Cell Signaling, 
8456), CyclinA2 (1:500, Abcam, ab7956), PABP (1:500, Santa Cruz, sc-32318), 
G3BP (1:1000, Abcam, ab56574), HA (1:1000, Sigma Aldrich, 11867423001) and 
GFP (1:1000, Cell Signaling, 2956). For quantification, images were processed using 
ImageJ. 
 
Immunoprecipitation experiments 
Cells were collected in lysis buffer lysis buffer (150 mM NaCl, 50 mM HEPES, 1% 
Triton X-100, 0.1% SDS, 5mM EDTA and 2x protease inhibitor cocktail in miliQ 
H2O), allowed to lyse on ice for 20 min. The cells were then centrifuged at 21,000 
RCF for 15 min at 40C and the supernatant was used for Immunoprecipitation 
experiments. The cleared lysates was diluted 10 fold in dilution buffer (150 mM 
NaCl, 50 mM HEPES and 5mM EDTA and 1x protease inhibitor cocktail), and then 
incubated with anti-GFP magnetic agarose beads (Chromotek) at 4 °C for 120 min on 
a rotory shaker. The beads were then washed thrice with wash buffer (150 mM NaCl, 
50 mM HEPES and 5mM EDTA). To pull down the immunocomplexes, beads were 
boiled in 30 µl of 2× SDS- PAGE sample buffer for 15 mins. The immunoprecipitated 
proteins were separated by SDS-PAGE. Western blot analysis was performed as 
previously described. 
 
Data availability 
The raw data that support the findings of this study are available from the 
corresponding author upon reasonable request. 
 
Mass spectrometry raw data 
Mass spectrometry raw data are available via ProteomeXchange with identifier 
PXD007761. 
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Figure Legends (Extended Data) 
 
Extended data Figure 1. DYRK3 interactions are differentially regulated upon 
GSK-626616 treatment 
 
a 
Experimental design of SILAC quantitative pull-down assays to identify protein-
protein interaction partners of DYRK3. 
b 
Experimental design of triple-SILAC quantitative pull-down assays to identify 
changes of DYRK3 interactors upon GSK-626616 inhibitor treatment.  
c 
Scatter plot shows changes of DYRK3 interactors upon GSK-626616 inhibitor 
treatment (normalized H/M log2 ratios). Only proteins detected as DYRK3 specific 
interactors (normalized H/L or M/L log2 ratio > 1) were retained on this plot. 
Interactors are considered differentially regulated (colored rims) if the H/M log2 ratio 
is greater than 1 or less than -1. 
d 
Mean intensity of DYRK3 interactors upon GSK-626616 inhibitor treatment 
(representative of two technical replicates).  
e 
Protein abundance of DYRK3 interactors and DYRK3 upon GSK-626616 inhibitor 
treatment (representative of two independent experiments). 
 
Box plots: central mark: population median; box: interquartile range; whiskers: 1st/3rd 
quartile ± 1.5* interquartile range; outliers: dots. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 2. GSK-626616 inhibited DYRK3 localizes to stress 
granules and forms mitotic granules 
 
a 
Western blot shows expression level of endogenous DYRK3 and GFP-DYRK3 in 
HeLa Flp-In T-Rex cells stably expressing inducible GFP-wildtype DYRK3. GFP-
DYRK3 expression was induced by doxycycline (500ng/mL, 4hrs). Same induction 
conditions were used for Fig. 1c-e and Extended data 2b). 
b 
Colocalization of GSK-626616 inhibited (1µM, 2hrs) GFP-wildtype DYRK3 with 
stress granules upon arsenite treatment (500µM, 45mins). 
c 
Mitotic cells show formation of small DYRK3-positive granules upon GSK-626616 
treatment (1µM, 1hr). 
d 
Phosphoproteomic data of human cell cycle showing changes of regulated phospho-
sites that are associated with DYRK3 specific interactors detected in Fig. 1a. The 
majority (74.4%) of these phospho-sites reached peak level at mitosis. The phospho-
site occupancy level is displayed for those sites that were downregulated upon GSK-
626616 inhibitor treatment as reported in Wippich, et al. 2013. The phosphoproteomic 
data were retrieved from Olsen, et al. 2010. The known localization (splicing speckle, 
stress granule or centrosome) of the corresponding protein is indicated for each 
phospho-site. 
 
Images and western blot are representative of at least three independent experiments. 
Scale bars: 10 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 3. DYRK3 inhibition forms aberrant mitotic granules  
 
a 
Dissolved staining of splicing speckle marker (SC35) in mitotic cells upon DMSO 
treatment.  
b 
Dissolved staining of stress granule marker (PABP) in mitotic cells upon DMSO 
treatment. 
c 
Spindle pole localization of pericentriolar material protein (PCM1) in mitotic cells 
upon DMSO treatment. 
d 
Mitotic cells (HEK293T) show formation of SC35 granules upon GSK-626616 
treatment (1µM, 1hr). 
e 
Formation of SON granules in mitotic cells upon GSK-626616 treatment (1µM, 6hr). 
f 
Formation of TIAR granules in mitotic cells upon GSK-626616 treatment (1µM, 6hr). 
g 
Left: Quantification of fraction of mitotic (metaphase) cells with SC35 granules on 
treatment with kinase inhibitors (1µM, 1hr).  
Right: Quantification of fraction of mitotic (metaphase) cells with PABP granules on 
treatment with kinase inhibitors (1µM, 3hr). 
Inhibitors and the corresponding kinase targets are mentioned. Data are Mean ± SD 
(n=3 technical replicates) 
 
Images are representative of at least three independent experiments. Scale bars: 10 
µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 4. Formation of mitotic granules is DYRK3 specific 
 
a 
Mitotic cells show no colocalization between splicing speckle marker (SC35) and 
SRPK1 upon GSK-626616 treatment (1µM, 1hr). 
b 
Mitotic cells show no colocalization between splicing speckle marker (SC35) and 
CYCLIN B upon GSK-626616 treatment (1µM, 1hr). 
c 
Mitotic cells show no colocalization between splicing speckle marker (SRRM2) and 
CDK1 upon GSK-626616 treatment (1µM, 1hr). 
d 
Mitotic cells stained for pY15 CDK1. Loss of pY15 signal (CDK1 activation) in 
mitotic cells upon GSK-626616 (1µM, 1hr) treatment is comparable to DMSO 
control. 
e 
GSK-626616 treatment (1µM, 1hr) does not result in decrease in pT446 APC3 
(CDK1 mitotic substrate) signal in mitotic cells compared to DMSO control. 
f 
Mitotic cells show staining for pT446 APC3 (CDK1 mitotic substrate). The cells were 
pre-permeabilized with Triton-X before fixation. pT446 APC3 signal can be observed 
at spindle poles for both DMSO and GSK-626616 treatment (1µM, 1hr).  
g 
Appearance of SC35 granules and spindle apparatus defects upon DYRK3 
knockdown.  
Right: Quantification of SC35 granule number in mitotic (metaphase) cells (4 
independent experiments).  
 
Box plots: central mark: population median; box: interquartile range; whiskers: 1st/3rd 
quartile ± 1.5* interquartile range; outliers: dots. Statistical analysis performed across 
cells by Welch two-sided t-test. 
 
Images and data are representative of at least three independent experiments. Scale 
bars: 10 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 5. Inhibition of DYRK3 does not affect all membrane-less 
organelles in mitosis 
 
a 
Colocalization of splicing marker and Poly(A) mRNA in hybrid compartments in 
mitotic cells upon GSK-626616 treatment (1µM, 3hr) 
b 
Colocalization of splicing marker and GFP-wildtype DYRK3 in hybrid compartments 
in mitotic cells upon GSK-626616 treatment (1µM, 2hrs) 
c 
Dissolution of P-bodies (DDX6) in mitotic cells is unaffected upon GSK-626616 
treatment (1µM, 6hrs). 
d 
Dissolution of nucleoli (Fibrillarin) in mitotic cells is unaffected upon GSK-626616 
treatment (1µM, 6hrs). 
e 
Dissolution of Cajal bodies (Coilin) in mitotic cells is unaffected upon GSK-626616 
treatment (1µM, 6hrs). 
f 
Aberrant granules formed upon GSK-626616 treatment are not ubiquitinated 
aggregates. 
 
Images and data are representative of at least three independent experiments. Scale 
bars: 10 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 6. Protein abundance does not change during formation of 
mitotic granule upon GSK-626616 inhibitor treatment 
 
a 
Time-lapse images (single Z-stack) show fusion of mitotic SRRM2-mCherry granules 
formed in the presence of GSK-626616 inhibitor (1µM) in cells arrested in mitosis 
(thymidine-nocodazole block). 
b 
Mean cell intensity of SRRM2-mCherry is plotted during mitotic granule formation 
on addition of GSK-626616 inhibitor (1µM). Data are Mean ± SD. 
c 
Top: Mean intensity of SRRM2-mCherry in the dissolved phase is plotted during 
mitotic granule formation on addition of GSK-626616 inhibitor (1µM). 
Bottom: Time-lapse images of the cells plotted in the top panel. 
 
Images are representative of at least three independent experiments. Scale bars: 10 
µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 7. Dissolution of membrane-less organelles is dependent on 
DYRK3 localization and its kinase activity  
 
a 
Images show cells overexpressing GFP-wildtype (WT) and kinase-dead (K218M) 
DYRK3. These images are the same as Fig. 3a showing both channels. 
b 
Dissolution of splicing speckles upon overexpressing GFP-wildtype (WT) DYRK3 in 
interphase cells is reversed by GSK-626616 treatment (1µM, 2hrs). 
c 
Top: Schematic representation of GFP-tagged NLS (Nuclear Localizing Signal) 
mutant of DYRK3. Arginine (R) and Lysine (K) residues in the NLS are mutated to 
Alanine (A). 
Bottom: Overexpressed GFP-tagged NLS mutant of DYRK3 localizes to the 
cytoplasm and does not dissolve splicing speckles. 
d 
Left: Dissolution of splicing speckles upon overexpressing GFP- NLS (SV40) tagged 
wildtype (WT) DYRK3 in interphase cells. 
Middle: Dissolution of splicing speckles upon overexpressing GFP- NLS (SV40) 
tagged wildtype (WT) DYRK3 in interphase cells is reversed upon GSK-626616 
treatment (1µM, 2hrs). 
Right: Condensed splicing speckles upon overexpressing GFP- NLS (SV40) tagged 
kinase-dead (K218M) DYRK3 in interphase cells. 
e 
Images show cells overexpressing GFP-wildtype (WT) and kinase-dead (K218M) 
DYRK3. These images are the same as Fig. 3c showing both channels. 
f 
Dissolution of pericentriolar satellites upon overexpressing GFP-wildtype (WT) 
DYRK3 in interphase cells is reversed upon GSK-626616 treatment (1µM, 2hrs). 
g 
Images show cells overexpressing GFP-wildtype (WT) and kinase-dead (K218M) 
DYRK3. These images are the same as Fig. 3e showing both channels. 
h 
Dissolution of stress granules upon overexpressing GFP-wildtype (WT) DYRK3 in 
interphase cells is reversed upon GSK-626616 treatment (1µM, 2hrs). 
i 
The percentage of low complexity regions (LCR) occupying each full-length protein 
was computed for all DYRK3 interactors (Fig. 1a) and all the known splicing speckle 
components (GO:0016607). SRRM1 shown in blue is among the proteins with the 
highest proportion of low complexity regions. 
j 
Dissolution of GFP-PCM1(1-1468) cytosolic granules upon overexpressing RFP- 
wildtype (WT) DYRK3, and not kinase-dead (K218M) DYRK3. 
k 
Time-lapse images show RFP-wildtype (WT) DYRK3 driven dissolution of cytosolic 
granules formed upon GFP-PCM1(1-1468) overexpression.  
 
 
 
 
l 
Dissolution of mCherry-SRRM1 nuclear granules upon overexpressing GFP-wildtype 
(WT) DYRK3, and not kinase-dead (K218M) DYRK3. 
 
m 
Nucleoli are unaffected upon overexpressing GFP-wildtype (WT) DYRK3 or kinase-
dead (K218M) DYRK3 in interphase cells. 
 
Images are representative of at least three independent experiments. All scale bars: 10 
µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 8. Dilution of DYRK3 substrates during G2 to M 
transition 
 
a 
Top: Time-lapse images of a cell (single Z-stack) expressing GFP-3xNLS (Nuclear 
Localizing Signal) during G2 to M transition.   
Bottom: Changes in mean nuclear intensity of GFP-3xNLS during G2 to M transition. 
The lines (background) show mean nuclear intensity for individual cells (n=11). Data 
are Mean ± SD. Time point (0 min) refers to nuclear envelope breakdown. 
b 
Top: Time-lapse images of a cell (single Z-stack) expressing pmScarlet-NES (Nuclear 
Export Signal) during G2 to M transition. 
Bottom: Changes in mean cytoplasmic intensity of pmScarlet-NES during G2 to M 
transition. The lines (background) show mean nuclear intensity for individual cells 
(n=8). Data are Mean ± SD. Time point (0 min) refers to nuclear envelope 
breakdown. 
c 
Top: Time-lapse images of a cell (single Z-stack) expressing GFP-wildtype DYRK3 
during G2 to M transition.  
Bottom: Changes in mean cytoplasmic intensity of GFP-wildtype DYRK3 during G2 
to M transition. The lines (background) show mean cytoplasmic intensity for 
individual cells (n=9). Data are Mean ± SD. Time point (0 min) refers to nuclear 
envelope breakdown. 
d 
Top: Time-lapse images of a cell (single Z-stack) expressing GFP-PCM1(1-1468) 
during G2 to M transition. 
Bottom: Changes in mean cytoplasmic intensity of GFP-PCM1(1-1468) during G2 to 
M transition. The lines (background) show mean nuclear intensity for individual cells 
(n=11). Data are Mean ± SD. Time point (0 min) refers to nuclear envelope 
breakdown. 
e 
Overexpressing mCherry-SRRM1 form mitotic granules which recruit endogenous 
splicing proteins. 
f 
Time-lapse images (single Z-stack) show fusion of mitotic mCherry-SRRM1 granules 
in mitotic cells. 
g 
Left: FRAP analysis of interphase and mitotic mCherry-SRRM1 granules in the 
presence and absence of GSK-626616 inhibitor (1µM). Data are Mean ± SD. 
Right: FRAP recovery of mitotic mCherry-SRRM1 granule. 
h 
Cells arrested in mitosis show formation of splicing granules upon GSK-626616 
treatment (1µM, indicated times). 
Data and images are representative of at least three independent experiments. Scale 
bars: 10 µm. 
 
 
 
 
 
Extended data Figure 9. Spindle apparatus defects upon DYRK3 inhibition 
 
a 
Multiple γ-tubulin foci in mitotic cells upon GSK-626616 treatment (1µM, 6hr).  
b 
Top: ZNF207 localization in interphase cells (No pre-permeabilization). 
Bottom: ZNF207 and SC35 colocalize in Triton-X pre-permeabilized interphase cells. 
c 
ZNF207 granules in mitotic cells upon GSK-626616 treatment (1µM, 3hr). 
d 
GFP-wildtype (WT) DYRK3 colocalizes with ZNF207 in mitotic cells upon GSK-
626616 treatment (1µM, 3hr). GFP-wildtype DYRK3 expression was induced in 
HeLa Flp-In T-Rex cells by adding doxycycline (500ng/mL, 6hrs). 
 
Images are representative of at least three independent experiments. Scale bars: 10 
µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended data Figure 10. DYRK3 forms ubiquitin-positive aggregates on 
overexpression of Cdc20 and Cdh1 or upon proteosomal inhibition 
 
a 
Ubiquitin does not colocalize with overexpressed GFP inside cells. 
b 
Ubiquitin localizes to GFP-wildtype DYRK3 aggregates, formed on HA-Cdh1 and 
HA-Cdc20 overexpression. 
c 
Ubiquitin does not colocalize with overexpressed GFP upon MG-132 treatment 
(5µM, 4hrs). 
d 
Ubiquitin localizes to GFP-wildtype DYRK3 granules upon MG-132 treatment (5µM, 
4hrs). GFP-wildtype DYRK3 expression was induced in HeLa Flp-In T-Rex cells by 
adding doxycycline (500ng/mL, 6hrs). 
e 
Top: GFP-wildtype DYRK3 overexpression prevents re-assembly of cytosolic 
mCherry-SRRM1 granules during late mitosis. 
Bottom: GFP-wildtype DYRK3 overexpression prevents re-assembly of cytosolic 
splicing granules during late mitosis. 
 
Images are representative of at least three independent experiments. Scale bars: 10 
µm 	
















